预约演示
Click Therapeutics teams up with addiction treatment maker Indivior to make digital therapeutics for substance use disorders
临床3期突破性疗法临床2期
The partnership between Click Therapeutics and Invidior will combine Click’s AI technology with Indivior's decades of expertise in the field of substance use disorders to create multiple digital therapeutic programs that provide behavioral therapy and other psychosocial treatments.
As it builds out a pipelClick Therapeuticsrapeutics spanning a wide rClickof conditions—from smoking cessation to depression to schizophrenia—Clsubstance use disordersde a habit of turning to the experts in those treatment areas for help.
It’s upholding that tradition as it constructs a digital program to help treat a variety of substance use disorderdepressionnnouschizophrenia Click Therapeutics Indivior, the British drugmaker behind Suboxone and a variety of other addiction-targeting therapeutics, to share its expertise in that arena as the development process begins.
The partnership will focus first on opioid use disorder, or OUD. The duo will start with a “substance use disorders phase,” during which they’ll define the scope of an app-based digital therapeutic—cuSuboxonedubbed CT-102—that could be used to help treat the condition in tandem with a pharmacological regimen. This exploratory phase will stretch into 2024, the partners said, after which they’ll lay out a longer-term development plan.
Click will be leading the creation oopioid use disorderrespoOUDbility for all technical and clinical development, necessary regulatory filings and other steps on the way to commercialization. Indivior, meanwhile, wiCT-102—thatbal rights to license the resulting digital therapeutic.
The companies didn’t offer up financiaCT-102s of their collaboration but said in the release that Click will be eligible to receive “double-digit royalties” on Indivior’s global sales of the technology as well as upfront license and early development payments and milestone payouts as the product hits certain regulatory and commercial benchmarks.
And the OUD app is set to be just the beginning of what Click and Indivior have termed a multiprodClickollaboration—giving Click the potential to reap even bigger rewards if the duo rolls out additional digital therapeutics in the future.
Throughout this and all future development work, they’re planning to combine Click’s artificial-intelligence-powered technology with the pharma’s decades of expertise in the field of substance use disorders to create multiple digital therapeutic programs that provide behavioral therapy and other psychosocial treatments for the conditions. These treatments can be beneficial when used alongside a prescribed drug regimen but may not always be easily accessible to individuals receiving addiction treatment, Click noted in the announcement.
The Indivior partnership on CT-102 marks the fourth of Click’s digital therapeutics to be developed in partnership with the pharmaceutical industry. An ongoing partnership with Boehrisubstance use disorderso of Click’s schizophrenia treatments—one of which is now in phase 3 pivotal trials—while Otsuka Pharmaceutical came aboard in 2019 to team up on a digital approach to treating major depressive disorder.
Outside of those pharma tie-CT-102n addition to its already launched Clickotine program for smoking cessation, Click is working solo on the development of digital therapeutics fBoehringer Ingelheiming insomnia, acute coschizophreniame, multiple sclerosis and migraine, the last of which recently Otsuka Pharmaceuticalesignation from the FDA.major depressive disorder
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。